Viridian Therapeutics, Inc.\DE (VRDN) Non Operating Income (2016 - 2026)

Viridian Therapeutics, Inc.\DE's Non Operating Income history runs 11 years deep, the most recent figure standing at $11.3 million for Q1 2026.

• On a quarterly basis, Non Operating Income rose 62.04% year-over-year to $11.3 million in Q1 2026; TTM through Mar 2026 was $25.1 million, a 12.47% decrease from a year earlier, with the FY2025 full-year figure at $20.8 million, down 28.51% from the prior year.
• Non Operating Income grew to $11.3 million in Q1 2026 per VRDN's latest filing, from $2.4 million in the prior quarter.
• Across five years, Non Operating Income topped out at $11.3 million in Q1 2026 and bottomed at $73000.0 in Q2 2022.
• The 5-year median for Non Operating Income is $4.6 million (2023), against an average of $4.8 million.
• Across the five-year window, Non Operating Income soared 5669.86% in 2023 and sank 69.1% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $3.3 million in 2022, then soared by 40.75% to $4.6 million in 2023, then jumped by 67.76% to $7.7 million in 2024, then sank by 69.1% to $2.4 million in 2025, then surged by 370.68% to $11.3 million in 2026.
• Per Business Quant, the three latest VRDN Non Operating Income figures stand at $11.3 million (Q1 2026), $2.4 million (Q4 2025), and $5.4 million (Q3 2025).